Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 266 | 26 | 237 |
| Samples | 259 | 25 | 231 |
| Peptides | 192 | 24 | 175 |
Function
CCDC155 · Protein KASH5
As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex, involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. Required for telomere attachment to nuclear envelope in the prophase of meiosis (PubMed:35587281). Required for rapid telomere prophase movements implicating a SUN1/2:KASH5 LINC complex in which SUN1 and SUN2 seem to act at least partial redundantly. Required for homolog pairing during meiotic prophase in spermatocytes and probably oocytes. Essential for male and female gametogenesis (PubMed:35587281). Recruits cytoplasmic dynein to telomere attachment sites at the nuclear envelope in spermatocytes. In oocytes is involved in meiotic resumption and spindle formation
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000447857 | Q8N6L0 | 266 | 192 |
Gene Properties
Recurrent Mutations
All 192 amino-acid changes on canonical ENST00000447857 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCDC155 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCDC155 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 14/612 2% |
| Melanoma | 3/210 1% | 42/1899 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Bladder Carcinoma | 2/58 3% | 11/956 1% |
| Other Solid Cancers | 0/94 0% | 18/1515 1% |
| Gastric Carcinoma | 1/74 1% | 19/1809 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Colorectal Carcinoma | 4/143 3% | 22/3239 1% |
| Neuroendocrine Tumour | 4/154 3% | 0/577 0% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 5/1390 0% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Glioma | 0/52 0% | 11/2127 1% |
| Kidney Carcinoma | 0/85 0% | 9/1862 0% |
| Ovarian Carcinoma | 0/109 0% | 5/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 7/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 9/2210 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Breast Carcinoma | 0/144 0% | 13/3264 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Pancreatic Carcinoma | 0/89 0% | 5/1611 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 5/2550 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
Mutation Distribution
Where CCDC155 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCDC155 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 266 mutations in CCDC155
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|